Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
doi 10.21693/1933-088x-17.2.69
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pulmonary Hypertension Association

Related search

Liposomal Fasudil, a Rho-Kinase Inhibitor, for Prolonged Pulmonary Preferential Vasodilation in Pulmonary Arterial Hypertension

Journal of Controlled Release
Pharmaceutical Science
2013English

P11 Tyrosine Kinase Inhibitor Use in Pulmonary Adenocarcinoma

Thorax
PulmonaryRespiratory Medicine
2013English

Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Pulmonary Arterial Hypertension

Current Problems in Cardiology
MedicineCardiovascular MedicineCardiology
2011English

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor–Induced Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Acute Effects of Rho-Kinase Inhibitor Fasudil on Pulmonary Arterial Hypertension in Patients With Congenital Heart Defects

Circulation Journal
MedicineCardiovascular MedicineCardiology
2015English

Checkpoint Kinase 1 Promotes the Development of Pulmonary Arterial Hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2019English

Antioxidant Treatment Attenuates Pulmonary Arterial Hypertension-Induced Heart Failure

American Journal of Physiology - Heart and Circulatory Physiology
Cardiovascular MedicinePhysiologyCardiology
2010English

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Frontiers in Pharmacology
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy